HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.400
-0.039 (-8.88%)
At close: Apr 28, 2026, 4:00 PM EDT
0.390
-0.010 (-2.50%)
Pre-market: Apr 29, 2026, 5:45 AM EDT
HCW Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.05 | 2.57 | 2.84 | 6.72 | - | |
| Revenue Growth (YoY) | -97.89% | -9.68% | -57.73% | - | - | |
| Cost of Revenue | 0.04 | 1.61 | 2.28 | 4.14 | - | |
| Gross Profit | 0.01 | 0.96 | 0.56 | 2.59 | - | |
| Selling, General & Admin | 8.34 | 22.83 | 13.44 | 8.41 | 5.3 | |
| Research & Development | 5.33 | 6.29 | 7.59 | 9.25 | 8.07 | |
| Operating Expenses | 13.67 | 29.12 | 26.28 | 17.67 | 13.37 | |
| Operating Income | -13.66 | -28.16 | -25.72 | -15.08 | -13.37 | |
| Interest Expense | -0.85 | -0.65 | -0.28 | -0.13 | - | |
| Other Non Operating Income (Expenses) | -0.2 | 0.09 | 0.76 | 0.49 | -0.06 | |
| EBT Excluding Unusual Items | -14.7 | -28.72 | -25.24 | -14.71 | -13.43 | |
| Gain (Loss) on Sale of Investments | -0.27 | - | 0.25 | -0.19 | - | |
| Asset Writedown | -1.5 | - | - | - | - | |
| Other Unusual Items | 6.52 | -1.3 | - | - | 0.57 | |
| Pretax Income | -7.96 | -30.02 | -24.99 | -14.9 | -12.86 | |
| Net Income | -7.96 | -30.02 | -24.99 | -14.9 | -12.86 | |
| Preferred Dividends & Other Adjustments | 14.34 | - | - | - | - | |
| Net Income to Common | -22.3 | -30.02 | -24.99 | -14.9 | -12.86 | |
| Shares Outstanding (Basic) | 2 | 1 | 1 | 1 | 0 | |
| Shares Outstanding (Diluted) | 2 | 1 | 1 | 1 | 0 | |
| Shares Change (YoY) | 116.30% | 7.97% | 0.30% | 90.84% | 296.07% | |
| EPS (Basic) | -10.63 | -30.96 | -27.83 | -16.64 | -27.41 | |
| EPS (Diluted) | -10.63 | -30.96 | -27.83 | -16.64 | -27.41 | |
| Free Cash Flow | -13.39 | -14.49 | -28.72 | -20.66 | -11.02 | |
| Free Cash Flow Per Share | -6.38 | -14.94 | -31.97 | -23.07 | -23.49 | |
| Gross Margin | 20.00% | 37.38% | 19.72% | 38.48% | - | |
| Operating Margin | -25192.71% | -1096.95% | -904.96% | -224.32% | - | |
| Profit Margin | -41117.24% | -1169.70% | -879.52% | -221.67% | - | |
| Free Cash Flow Margin | -24693.20% | -564.48% | -1010.51% | -307.36% | - | |
| EBITDA | -12.62 | -26.97 | -24.58 | -14.49 | -12.82 | |
| EBITDA Margin | - | - | - | -215.55% | - | |
| D&A For EBITDA | 1.04 | 1.18 | 1.14 | 0.59 | 0.54 | |
| EBIT | -13.66 | -28.16 | -25.72 | -15.08 | -13.37 | |
| EBIT Margin | - | - | - | -224.32% | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.